Enterprise Value

264.2M

Cash

203.8M

Avg Qtr Burn

-19.34M

Short % of Float

8.58%

Insider Ownership

6.41%

Institutional Own.

86.67%

Qtr Updated

06/30/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Acazicolcept (ALPN-101) Details
Systemic lupus erythematosus

Phase 2

Data readout

Povetacicept (ALPN-303) Details
Autoimmune disease, Systemic lupus erythematosus

Phase 2

Initiation

Povetacicept (ALPN-303) Details
Autoimmune disease, Primary immune thrombocytopenia

Phase 1b

Data readout

Povetacicept (ALPN-303) Details
Autoimmune disease, Autoimmune nephritis, Immune complex membranoproliferative glomerulonephritis

Phase 1b

Data readout

Failed

Discontinued